The loss of retinal ganglion cells (RGCs) is a prevalent characteristic of glaucoma and often the reason behind disease progression. Now, a team of researchers has utilized AI to identify a RIPK3 ...
Momentum Therapeutics Inc. has described receptor-interacting serine/threonine-protein kinase 3 (RIPK3) inhibitors reported to be useful for the treatment of systematic inflammatory response syndrome, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results